Ideal for clinical trials of fully bioabsorbable arterial stents
Release date: 2007-05-28 Clinical trial results for fully bioabsorbable arterial stents Recently, medical device manufacturer Abbott announced that the world's first clinical trial to evaluate the overall safety and feasibility of a fully bioabsorbable stent for the treatment of coronary artery disease is ideal. At the 56th ACC Scientific Chapter in New Orleans, the company announced the results of a choice of 30 patients for 6 months, showing no thrombosis, and a low incidence of ischemic major cardiac events such as cardiac events or repeated interventions ( 3.3%). The results of the trial confirmed that the therapeutic effect of the fully bioabsorbable drug stent everolimus is similar to that observed in Abbott's study, and that everolimus is effective in inhibiting the proliferation of arterial intimal tissue. The rate at which the fully bioabsorbable drug stent was successfully placed on the lesion was 93.5%. The everolimus-eluting stent consists of polylactic acid, which is a biocompatible substance that is absorbable and is commonly used in medical implant materials. ——Midi Medical Network Folding wheelchair for the old , Portable folding wheelchair for the disabled,Portable electric wheelchair for disability jinan Fangqi Sunshine education consulting CO.,LTD. , https://www.fzrehabmarket.com